Massive Bio Launches Patient Connect: A Revolutionary Platform for Global Cancer Clinical Trial Access
Massive Bio, a global frontrunner in AI-driven cancer clinical trial enrollment, has unveiled Patient Connect, a groundbreaking and free portal designed to guide cancer patients through their clinical trial journey worldwide.
Patient Connect empowers patients by streamlining their search for suitable clinical trials in their preferred language. By consenting to share their medical records, patients enable Massive Bio’s AI-driven multi-trial matching system to analyze their specific diagnosis, biomarkers, treatment history, and geographic location, identifying the most relevant clinical trial options. This approach is aimed at overcoming financial and geographical barriers, expanding access to potential treatments. Patients can also download personalized trial matching reports and share them with their physicians and loved ones, facilitating more informed decisions about their cancer care.
With Patient Connect, over 132,000 patients onboarded by Massive Bio can now access their personalized matching results for nearly 16,000 cancer trials. Massive Bio’s AI platform has successfully matched patients to over 33,000 clinical trial sites, showcasing its scalability. Recent research presented at ASCO 2024 in collaboration with the Precision Cancer Consortium revealed that Massive Bio’s unique multi-trial matching approach can increase patient eligibility for clinical trials by up to 12-fold.
Dr. Arturo Loaiza-Bonilla, Chief Medical Officer and Co-Founder of Massive Bio, remarked, “Patient Connect redefines patient engagement with clinical trials, providing a lifeline to new treatment opportunities and fostering hope for improved outcomes.”
In addition to its technological innovations, Massive Bio offers personalized support through its concierge services. Patient relations coordinators, MDs, and oncology nurses assist patients with inquiries, guidance, and the final steps of the enrollment process, including site referrals, logistical issues, and financial assistance needs, ensuring a seamless transition from referral to trial participation.
“Patient Connect enables patients to navigate the clinical trial process intuitively while maintaining connections with their physicians and loved ones throughout their journey,” said Oz Hüner, Chief Product Officer of Massive Bio.
Engagement with oncologists and hematologists is crucial. Using the Massive Bio Clinical Network, treating physicians can review pre-screening results and effectively manage their patients’ enrollment process. Massive Bio’s integration of patient and provider engagement represents a pioneering advancement in global clinical trial enrollment.
